Acute Myeloid Leukemia - Heat Map and Analysis
Report Description
Acute Myeloid Leukemia (AML) is a rare but serious disease, and the most common leukemia suffered by adults.
The first-line treatment in eligible patients is almost always intensive chemotherapy.
Despite strong initial remission rates, relapse is common, and AML has the lowest five-year survival rate of all leukemias, at 25%. Efforts have been made to introduce novel therapies to the AML market, but its treatment has changed little in the last 40 years.
However, a number of products are currently in late-stage development for the treatment of AML, both before and after the induction of remission and relapse.
GET 20% DISCOUNT ON THIS REPORT
Continued…
Scope • What are the clinical characteristics of currently approved therapies for AML, in terms of specific safety and efficacy parameters? • What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them? • A number of pipeline therapies are in the late-stage pipeline for the postrelapse setting, but do they have sufficient differentiating characteristics to make a strong impact on the market and clinic?
Download Report Sample @ https://www.24marketreports.com/request-sample/ac ute-myeloid-leukemia---heat-map-and-analysis
Table of content 1 Table of Contents 2 2 Introduction 3 2.1 Report Guidance 3
3 Marketed Products 4 3.1 Intensive Remission Induction Therapy 4 3.2 Non-Intensive Remission Induction Therapy 4 3.3 Consolidation Therapy 4 3.4 Salvage Chemotherapy 5
Visit us at : https://www.24marketreports.com/life-sciences/ac ute-myeloid-leukemia---heat-map-and-analysis
Stay With Us:
TELEPHONE: (+1) 646 781 7170 Email: help@24marketreports.com
New York City Zone 01, United States,.